RAD001 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tuberous Sclerosis Complex
Conditions
Tuberous Sclerosis Complex
Trial Timeline
Jan 1, 2011 → Dec 1, 2014
NCT ID
NCT01289912About RAD001 + Placebo
RAD001 + Placebo is a phase 2 stage product being developed by Novartis for Tuberous Sclerosis Complex. The current trial status is completed. This product is registered under clinical trial identifier NCT01289912. Target conditions include Tuberous Sclerosis Complex.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02991807 | Phase 1/2 | Completed |
| NCT01289912 | Phase 2 | Completed |
| NCT00466102 | Phase 2 | UNKNOWN |
| NCT00410124 | Phase 3 | Completed |
Competing Products
13 competing products in Tuberous Sclerosis Complex
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Everolimus (RAD001) + Everolimus Placebo | Novartis | Phase 3 | 77 |
| Everolimus + Placebo | Novartis | Phase 3 | 77 |
| RAD001 | Novartis | Phase 1/2 | 41 |
| Placebo + Everolimus (RAD001) | Novartis | Phase 2 | 52 |
| RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase) | Novartis | Phase 3 | 77 |
| Everolimus | Novartis | Phase 1/2 | 41 |
| everolimus (RAD001) | Novartis | Phase 1/2 | 41 |
| everolimus | Novartis | Phase 3 | 77 |
| sirolimus | Pfizer | Phase 2 | 51 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| GWP42003-P + Placebo | Jazz Pharmaceuticals | Phase 3 | 74 |
| Cannabidiol Oral Solution [Epidiolex] | Jazz Pharmaceuticals | Approved | 82 |